Glucagon: In-Depth Analysis of Its Mechanism and Application Scope
Abstract: Glucagon, a 29-amino acid peptide hormone, primarily elevates blood glucose via hepatic glycogenolysis. Its mechanism involves G-protein-coupled receptor activation, stimulating cAMP production. In the peptide industry, glucagon-based products (e.g., injectable glucagon, intranasal formulations) show a 7.2% CAGR (2023-2030), driven by diabetes and hypoglycemia management. Brand comparison reveals Novo Nordisk’s GlucaGen® dominates with 62% market share, while Eli Lilly’s Baqsimi® offers non-invasive delivery. Technical advantages include rapid onset (5-15 min) and high specificity; limitations include short half-life (8-18 min) and cold-chain logistics (2-8°C). Product parameters: purity ≥98% (HPLC), potency 1 mg/mL. Applications extend to diagnostic imaging (gastrointestinal motility) and metabolic research. Industry trends emphasize biosimilar development and lyophilized formulations for stability. Key certifications: FDA, EMA, GMP. Selection criteria prioritize stability, bioavailability, and regulatory compliance.